4.6 Article

Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort

Journal

JOURNAL OF CANCER
Volume 13, Issue 5, Pages 1706-1712

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/jca.63509

Keywords

prostate specific membrane antigen; papillary renal cell carcinoma; kidney cancer

Categories

Funding

  1. Deutsche Forschungsgemeinschaft
  2. Heidelberg University

Ask authors/readers for more resources

This study analyzed the expression of PSMA in papillary RCC (pRCC) type 1 and type 2, and evaluated the potential of PSMA-targeted imaging and treatment in pRCC. The results showed that PSMA staining was positive in a small percentage of type 1 pRCC samples, while no PSMA expression was detected in type 2 pRCC samples in this large cohort. These findings suggest limited expression of PSMA in pRCC, and further analysis in this subtype is not encouraged based on current clinical evaluation of PSMA expression in RCC.
Prostate specific membrane antigen (PSMA) is an emerging diagnostic and therapeutic target in prostate cancer. 68 Ga-PSMA-labeled hybrid imaging is used for the detection of prostate primary tumors and metastases. Therapeutic applications such as Lutetium-177 PSMA radionuclide therapy or bispecific antibodies that target PSMA are currently under investigation within clinical trials. The expression of PSMA, however, is not specific to prostate-tissue. It has been described in the neovascular endothelium of different types of cancer such as breast cancer, and clear cell renal cell carcinoma (ccRCC). The aim of this study was to analyze PSMA expression in papillary RCC (pRCC) type 1 and type 2, the most common non-ccRCC subtypes, and to evaluate the potential of PSMA-targeted imaging and treatment in pRCC. Formalin-fixed, paraffin-embedded tissue samples of primary tumors were analyzed for PSMA expression by immunohistochemistry. Out of n=374 pRCC specimens from the multicenter PANZAR consortium, n=197 pRCC type 1 and n=110 type 2 specimens were eligible for analysis and correlated with clinical data. In pRCC type 1 PSMA staining was positive in 4 of 197 (2.0%) samples whereas none (0/110) of the pRCC type 2 samples were positive for PSMA in this large cohort of pRCC patients. No significant PSMA expression was detected in pRCC. Reflecting current clinical evaluation of PMSA expression in RCC do not encourage further analysis in papillary subtypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available